A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
V García-Gutiérrez, M Breccia, E Jabbour… - Journal of Hematology & …, 2022 - Springer
Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with
chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second-and third …
chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second-and third …
Evolution of therapies for chronic myelogenous leukemia
FPS Santos, H Kantarjian, A Quintás-Cardama… - The Cancer …, 2011 - journals.lww.com
The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed
dramatically in the past 15 years. This has been due to the development of tyrosine kinase …
dramatically in the past 15 years. This has been due to the development of tyrosine kinase …
Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety
V García-Gutiérrez, JC Hernández-Boluda - Frontiers in oncology, 2019 - frontiersin.org
Chronic myeloid leukemia (CML) is currently a disease in which patients can enjoy a near
normal life-expectancy. However, since the majority of patients will need to remain on …
normal life-expectancy. However, since the majority of patients will need to remain on …
Treatments for chronic myeloid leukemia: a qualitative systematic review
R Ferdinand, SA Mitchell, S Batson… - Journal of blood …, 2012 - Taylor & Francis
Background Chronic myeloid leukemia (CML) is a myeloproliferative disorder of blood stem
cells. The tyrosine kinase inhibitor (TKI) imatinib was the first targeted therapy licensed for …
cells. The tyrosine kinase inhibitor (TKI) imatinib was the first targeted therapy licensed for …
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase …
P Jain, H Kantarjian, ML Alattar, E Jabbour… - The Lancet …, 2015 - thelancet.com
Background Several tyrosine kinase inhibitors (TKIs) are available for treatment of patients
with chronic myeloid leukaemia in chronic phase (CML-CP). We analysed long-term …
with chronic myeloid leukaemia in chronic phase (CML-CP). We analysed long-term …
Chronic myeloid leukemia, version 2.2024, nccn clinical practice guidelines in oncology
NP Shah, R Bhatia, JK Altman, M Amaya… - Journal of the National …, 2024 - jnccn.org
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …
Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology
MW Deininger, NP Shah, JK Altman, E Berman… - Journal of the National …, 2020 - jnccn.org
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …
Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology
JP Radich, M Deininger, CN Abboud, JK Altman… - Journal of the National …, 2018 - jnccn.org
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …
[HTML][HTML] Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review
MM Sampaio, MLC Santos, HS Marques… - World journal of …, 2021 - ncbi.nlm.nih.gov
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …
Third-line therapy for chronic myeloid leukemia: current status and future directions
J Cortes, F Lang - Journal of Hematology & Oncology, 2021 - Springer
Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …